BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Datamonitor Report: Price is Right for Sanofi-Aventis (France) (SASY.PA) – Analyst Comment


2/16/2011 10:14:43 AM

16th February 2011 -- Sanofi-aventis announced that it reached an agreement to acquire Genzyme for $74 per share in cash, or around $20.1 billion, along with a series of payments linked to sales and production milestones.

John Shortmoor, independent pharmaceutical companies analyst at Datamonitor, comments:

“This is a great deal for Sanofi, paying close to their original budget of $20 billion, with extra contingency payments only coming if Genzyme's multiple sclerosis drug Lemtrada exceeds Sanofi's expectations.

“Through the acquisition, Sanofi has succesfully gained access to niche markets where competition is limited by more than just patent protection - a stated aim of the company's CEO, Christopher Viehbacher - providing a platform for long-term sales growth, diversifying away from the traditional blockbuster model

“Moreover, through its strong global presence, Sanofi is in a good position to extend the geographic reach of Genzyme's portfolio, especially in growth markets, bolstering the company's long-term sales potential”

To arrange an interview or for further details regarding this release please contact Joe Dixonin the Datamonitor press office on + 44 (0)161 238 4083, or email jdixon@datamonitor.com

ABOUT DATAMONITOR

The Datamonitor Group (www.datamonitor.com) is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Sourcing, Technology and Telecoms industries. Combining our industry knowledge and experience, we assist more than 6,000 of the world’s leading companies in making better strategic and operational decisions.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES